Skip to main content
OpenTrials
Completed

NCT Number: NCT01483560

REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)

The trial is conducted in the United Kingdom (UK), Australia, Canada, Denmark and the Netherlands. The aim is to test whether 3 years treatment with metformin added to titrated insulin therapy (towards target HbA1c 7.0%/53 mmol/mol) reduces atherosclerosis, as measured by progression of carotid intima-media thickness (cIMT), in adults with confirmed type 1 diabetes aged 40 years and over at increased risk for cardiovascular disease.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Royal Melbourne Hospital, Melbourne, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type 1 Diabetes for five years or more*
  • Age 40 years or above
  • 7.0 =< HbA1c <10.0% (53 - 86 mmol/mol)

AND 3 or more of the following ten CardioVascular Disease (CVD) risk factors:

  • BMI >27 kg/m^2
  • Current HbA1c >8.0% (64 mmol/mol)
  • Known CVD/peripheral vascular disease
  • Current smoker
  • Estimated glomerular filtration rate (eGFR) <90 ml/min per 1.73 m^3
  • Confirmed micro- or macroalbuminuria [according to local assays and reference ranges]
  • Hypertension (BP >=140/90 millimeters of mercury (mmHg) or established on antihypertensive treatment)
  • Dyslipidaemia [total cholesterol >=5.0 mmol/L (200 mg/dL);OR HDL cholesterol <1.20 mmol/L (46mg/dL) [MEN]; OR <1.30 mmol/L (50 mg/dL) [WOMEN]; or triglycerides >=1.7 mmol/L (150mg/dL); or established on lipid-lowering treatment)]
  • Strong family history of CVD (at least one parent, biological aunt/ uncle, or sibling with myocardial infarction or stroke aged <60 years)
  • Duration of diabetes > 20 years

Exclusion criteria

  • eGFR < 45 ml/min/1.73m2
  • woman of childbearing age not on effective contraception
  • Pregnancy and/or lactation
  • Acute coronary syndrome or Stroke/Transient Ischaemic Attack within the last three months
  • NYHA stage 3 or 4 heart failure
  • Significant hypoglycaemia unawareness
  • Impaired cognitive function/ unable to give informed consent
  • Previous carotid surgery/ inability to capture adequate carotid images
  • Estimated glomerular filtration < 45ml/min/1.73m^2 (MDRD)
  • Gastroparesis
  • History of lactic acidosis
  • Other contraindications to metformin (hepatic impairment, known hypersensitivity to metformin, acute illness such as dehydration, severe infection, shock, acute cardiac failure or suspected tissue hypoxia)
  • Any coexistent life threatening condition including prior diagnosis of cancer within two years
  • History of alcohol problem or drug abuse

Treatment and study plan

metformin

Drug

3 years treatment duration

Other names: Glucophage

Placebo

Drug

3 years duration

Primary outcomes

  1. Change in Averaged Mean Far Wall Common Carotid Artery Intima-media Thickness (cIMT)

    Time frame: 0, 12 months, 24 months, 36 months

    Progression of averaged mean far wall common carotid artery intima media thickness IMT (mean cIMT) measured using B mode ultrasonography with a 7.0 MHz or higher broadband linear array transducer and concurrent recording of 3-lead electrocardiogram (ECG). Longitudinal images of the common carotid artery will be obtained at anterior, lateral and posterior angles at baseline, 12, 24 and 36 months using Meijer's arc to standardize the transducer angle.

Secondary outcomes

  1. Change in HbA1c

    Time frame: Baseline, Year 3

    Measured in accredited local laboratories participating in DCCT-aligned quality control programmes.

  2. Change in LDL Cholesterol

    Time frame: Baseline, Year 3

    mmol/L Centrally assayed at the University of Glasgow

  3. Change in Estimated Glomerular Filtration Rate

    Time frame: Baseline, Year 1, Year 2, Year 3

    Number of participants developing new microalbuminuria; change in absolute concentration Calculated using the MDRD equation1 based on creatinine measured in accredited local laboratories

  4. Number of Participants With Retinopathy and at Least a 2 Stage Progression in Retinopathy From Baseline to 36 Months

    Time frame: Baseline, Year 3

    Two color 45° field retinal photographs (fields 1 and 2) from each eye at 0 and 36 months graded at the University of Wisconsin Ocular Epidemiology Reading Center (OERC) using the modified Airlie House classification scheme and the Early Treatment Diabetic Retinopathy Severity scale.

  5. Change in Weight

    Time frame: Baseline, Year 1, Year 2, Year 3

    Measured at sites using calibrated weighing scales

  6. Change in Insulin Dose

    Time frame: Baseline, Year 1, Year 2, Year 3

    Units/ kg body weight Extracted by study nurses from the Study Diary and reported on the study CRF using dedicated fields

  7. Change in Endothelial Function

    Time frame: Baseline, Year 1, Year 3

    In some centres (Arbitrary units) Reactive Hyperaemia Index using the ENDOPAT device (Itamar, Israel)

Sponsors and collaborators

Lead sponsor

University of Glasgow

Other

Collaborators

  • Imperial College London
  • Itamar-Medical, Israel
  • Juvenile Diabetes Research Foundation
  • Maastricht University Medical Center
  • Merck Serono S.A., Geneva
  • NHS Greater Glasgow and Clyde
  • Steno Diabetes Center Copenhagen
  • University of Dundee
  • University of Melbourne
  • University of Western Ontario, Canada
  • University of Wisconsin, Madison

Registry information

Official study title

Phase 3 Study of Metformin in Adults With Type 1 Diabetes

Acronym: REMOVAL

Important dates

Study start
2011
Primary completion
2017
Study completion
2017
First posted
Dec 1, 2011
Registry last updated
Jun 19, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.